Please login to the form below

Not currently logged in
Email:
Password:

Par elects new chairman

US generic drug manufacturer Par Pharmaceutical has elected president and CEO Patrick G LePore as chairman of the board of directors.

US generic drug manufacturer Par Pharmaceutical has elected president and CEO Patrick G LePore as chairman of the board of directors.

LePore, who joined Par's board in May 2006, has been president and CEO since September 2006.

LePore replaces John D Abernathy as chairman. Abernathy will remain a board member.

Joseph E Smith, a member of the board since 2004, has been named lead director. Prior to his retirement in 1997, he held leadership positions with Warner-Lambert.

On 9 August, Par's shares fell USD 0.73, or 3.5 per cent, to USD 20.03 in pm trading. Shares have traded between USD 15.50 and USD 30.68 over the past year.

10th August 2007

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Syneos Health™

Syneos Health™ is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract...

Latest intelligence

What challenges still face clinical trial recruitment and retention?
Discover the reasons for the current clinical trial recruitment challenges facing pharma and the life sciences industry, and how the search for solutions to the problem continues...
“Fake News” and Credibility in Medical Publishing
Natalie Yeadon from Impetus Digital shares her thoughts on fighting fake news in Pharma and healthcare....
Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...

Infographics